Johnson & Johnson (JNJ) Stock Price, News & Analysis

Company Overview

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension. Its portfolio includes medicines marketed under brands such as Stelara, Darzalex, Erleada and Tremfya.

The MedTech segment provides products and technologies used in surgery, orthopaedics, cardiovascular care, and vision care. Its offerings include surgical instruments and systems, orthopaedic implants, electrophysiology and other cardiovascular technologies, and contact lenses. Johnson & Johnson completed the separation of its consumer health business, now known as Kenvue, in 2023.

Joaquin Duato has served as Johnson & Johnson’s chief executive officer since January 2022 and became chairman of the board in 2022. The company’s history traces back to the development of sterile surgical products by brothers Robert Wood Johnson, James Wood Johnson and Edward Mead Johnson.

Key Stats

• Today's Range: $265.72 to $271.27
• 50-Day Range: $247.55 to $278.66
• 52-Week Range: $173.33 to $281.07
• Volume: 2.04 million shs
• Average Volume: 8.09 million shs
• Market Capitalization: $643.24 billion
• P/E Ratio: 30.92
• Dividend Yield: 2.01%
• Price Target: $272.83
• Consensus Rating: Moderate Buy

Johnson & Johnson Stock Analysis - MarketRank™

Johnson & Johnson scored higher than 93% of companies evaluated by MarketBeat, and ranked 29th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Johnson & Johnson has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 18 buy ratings, 6 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Johnson & Johnson is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Johnson & Johnson has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.25%

Earnings Growth

Earnings for Johnson & Johnson are expected to grow by 10.25% in the coming year, from $11.61 to $12.80 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Johnson & Johnson is 30.92, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.05.

Price to Earnings Ratio vs. Sector

The P/E ratio of Johnson & Johnson is 30.92, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.72.

Price to Earnings Growth Ratio

Johnson & Johnson has a PEG Ratio of 2.57. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Johnson & Johnson has a P/B Ratio of 7.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.90% of the float of Johnson & Johnson has been sold short.

Short Interest Ratio / Days to Cover

Johnson & Johnson has a short interest ratio ("days to cover") of 3.33, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Johnson & Johnson has recently decreased by 15.02%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Johnson & Johnson pays a meaningful dividend of 1.99%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Johnson & Johnson has been increasing its dividend for 64 years.

Dividend Coverage

The dividend payout ratio of Johnson & Johnson is 62.11%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 41.88% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.25

News Sentiment

Johnson & Johnson has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 107 news articles for Johnson & Johnson this week, compared to 10 articles on an average week.

Search Interest

Only 108 people have searched for JNJ on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

73 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 59% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,476,044.00 in company stock.

Percentage Held by Insiders

0.16% of the stock of Johnson & Johnson is held by insiders.

Percentage Held by Institutions

69.55% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/15/2026
• Record date for 9/8 Dividend: 8/25/2026
• Ex-Dividend for 9/8 Dividend: 8/25/2026
• Dividend Payable: 9/08/2026
• Today: 9/10/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/14/2026
• Deutsche Bank 2026 Healthcare Summit: 9/17/2026
• Next Earnings (Estimated): 10/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:JNJ
• CIK: 200406
• Web: www.jnj.com
• Phone: (732) 524-0400
• Fax: 732-214-0332
• Employees: 138,200
• Year Founded: 1886

Price Target and Rating

• Average Price Target for Johnson & Johnson: $274.13
• High Price Target: $320.00
• Low Price Target: $210.00
• Potential Upside/Downside: +2.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): $8.63
• Trailing P/E Ratio: 30.91
• Forward P/E Ratio: 22.97
• P/E Growth: 2.57
• Net Income: $26.80 billion
• Net Margins: 21.48%
• Pretax Margin: 25.73%
• Return on Equity: 32.42%
• Return on Assets: 13.35%

Debt

• Debt-to-Equity Ratio: 0.44
• Current Ratio: 1.09
• Quick Ratio: 0.81

Sales & Book Value

• Annual Sales: $94.19 billion
• Price / Sales: 6.82
• Cash Flow: $13.99 per share
• Price / Cash Flow: 19.06
• Book Value: $33.85 per share
• Price / Book: 7.88

Miscellaneous

• Outstanding Shares: 2,409,900,000
• Free Float: 2,406,042,000
• Market Cap: $642.77 billion
• Optionable: Optionable
• Beta: 0.24